• Abdelgawad, N., Tshavhungwe, M. (Phophi), Rohlwink, U., McIlleron, H., Abdelwahab, M. T., Wiesner, L., Castel, S., Steele, C., Enslin, J. (Nico), Thango, N. S., Denti, P., & Figaji, A. (2023). Population Pharmacokinetic Analysis of Rifampicin in Plasma, Cerebrospinal Fluid, and Brain Extracellular Fluid in South African Children with Tuberculous Meningitis. Antimicrobial Agents and Chemotherapy, 67(3). https://doi.org/10.1128/AAC.01474-22

  • Atoyebi, S., Montanha, M. C., Najjemba, L., Orrell, C., Jennings, L., Mugerwa, H., Kawuma, A., Ojara, F., Siccardi, M., & Denti, P. (2023). Physiologically-based pharmacokinetic modelling of drug-drug interactions between ritonavir-boosted atazanavir and rifampicin in pregnancy. BMJ Global Health, 8(Suppl 10). https://doi.org/10.1002/psp4.13268

  • Chirehwa, M. T., Resendiz-Galvan, J. E., Court, R., de Kock, M., Wiesner, L., de Vries, N., Harding, J., Gumbo, T., Warren, R., & Maartens, G. (2023). Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling. Antimicrobial Agents and Chemotherapy, 67(3), e01426-22. https://doi.org/10.1128/aac.01426-22

  • Cindi, Z., Kawuma, A. N., Maartens, G., Bradford, Y., Sokhela, S., Chandiwana, N., Venter, W. D. F., Wasmann, R. E., Denti, P., & Wiesner, L. (2023). Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV. Pharmacogenetics and Genomics, 33(4), 79–87. https://doi.org/10.1097/fpc.0000000000000495

  • Faggionato, E., Denti, P., Largajolli, A., Bertoldo, A., & DALLA MAN, C. (2023). A Comprehensive Nonlinear Mixed Effects Model of Glucose, Insulin, and C-Peptide Interaction during IVGTT. EIGHTH NATIONAL CONGRESS OF BIOENGINEERING-Proceedings, 8, 238–241.

  • Faggionato, E., Largajolli, A., Bertoldo, A., DALLA MAN, C., & Denti, P. (2023). Assessing insulin sensitivity, glucose effectiveness, and β-cell responsivity using an integrated glucose, insulin, and C-peptide minimal model. Abstracts of the Annual Meeting of the Population Approach Group in Europe.

  • Gafar, F., Wasmann, R. E., McIlleron, H. M., Aarnoutse, R. E., Schaaf, H. S., Marais, B. J., Agarwal, D., Antwi, S., Bang, N. D., & Bekker, A. (2023). Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis. European Respiratory Journal, 61(3). https://doi.org/10.1183/13993003.01596-2022

  • Galileya, L. T., Wasmann, R. E., Chabala, C., Rabie, H., Lee, J., Njahira Mukui, I., Hesseling, A., Zar, H., Aarnoutse, R., & Turkova, A. (2023). Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. PLoS Medicine, 20(11), e1004303. https://doi.org/10.1371/journal.pmed.1004303

  • Joubert, A., Joubert, A., van der Merwe, M., Norman, J., Castel, S., Denti, P., Sliwa, K., Maartens, G., Sinxadi, P., & Wiesner, L. (2023). Validation of a quantitative multiplex LC-MS/MS assay of carvedilol, enalaprilat, and perindoprilat in dried blood spots from heart failure patients and its cross validation with a plasma assay. Journal of Mass Spectrometry and Advances in the Clinical Lab, 27, 7–17. https://doi.org/10.1016/j.jmsacl.2022.12.003

  • Kawuma, A. N., Wasmann, R. E., Dooley, K. E., Maartens, G., & Denti, P. (2023). Drug–drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model. British Journal of Clinical Pharmacology, 89(3), 1216–1221. https://doi.org/10.1111/bcp.15604

  • Kawuma, A. N., Wasmann, R. E., Sinxadi, P., Sokhela, S. M., Chandiwana, N., F Venter, W. D., Wiesner, L., Maartens, G., Denti, P., & Aida Kawuma, C. N. (2023). Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. CPT: Pharmacometrics & Systems Pharmacology, 12(6), 821–830. https://doi.org/10.1002/PSP4.12955

  • Kengo, A., Gausi, K., Nabisere, R., Musaazi, J., Buzibye, A., Omali, D., Aarnoutse, R., Lamorde, M., Dooley, K. E., & Sloan, D. J. (2023). Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin. Antimicrobial Agents and Chemotherapy, 67(11), e00431-23. https://doi.org/10.1128/aac.00431-23

  • Kengo, A., Nabisere, R., Gausi, K., Musaazi, J., Buzibye, A., Omali, D., Aarnoutse, R., Lamorde, M., Dooley, K. E., & Sloan, D. J. (2023). Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard-versus high-dose rifampicin. Antimicrobial Agents and Chemotherapy, 67(11), e00430-23. https://doi.org/10.1128/aac.00430-23

  • Michelet, R., Aulin, L. B. S., Borghardt, J. M., Dalla Costa, T., Denti, P., Ibarra, M., Ma, G., Meibohm, B., Pillai, G. C., & Schmidt, S. (2023). Barriers to global pharmacometrics: educational challenges and opportunities across the globe. CPT: Pharmacometrics & Systems Pharmacology, 12(6), 743. https://doi.org/10.1002/psp4.12940

  • Mouksassi, S., de Greef, R., Denti, P., Sinxadi, P., Decloedt, E., & Pillai, G. (2023). The African applied pharmacometrics training (APT) fellowship: 1 year later. PAGE 32 (2023).

  • Mwita, J. C., Joubert, A., Saidu, H., Sani, M. U., Damasceno, A., Mocumbi, A. O., Sinxadi, P., Viljoen, C. A., Hoevelmann, J., & Gebreyesus, M. S. (2023). Objectively measured medication adherence using assays for carvedilol and enalaprilat in patients with heart failure in Mozambique and Nigeria. International Journal of Cardiology Cardiovascular Risk and Prevention, 19, 200213. https://doi.org/10.1016/j.ijcrp.2023.200213

  • Perumal, R., Naidoo, K., Naidoo, A., Letsoalo, M. P., Esmail, A., Joubert, I., Denti, P., Wiesner, L., Padayatchi, N., & Maartens, G. (2023). The impact of enteral feeding and therapeutic monitoring of rifampicin with dose escalation in critically ill patients with tuberculosis. International Journal of Infectious Diseases, 126, 174–180. https://doi.org/10.1016/j.ijid.2022.11.033

  • Resendiz-Galvan, J. E., Arora, P. R., Abdelwahab, M. T., Udwadia, Z. F., Rodrigues, C., Gupta, A., ... & Tornheim, J. A. (2023). Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India. Frontiers in Pharmacology13, 1081123. https://doi.org/10.3389/fphar.2022.1081123

  • Salerno, S. N., Capparelli, E. v, McIlleron, H., Gerhart, J. G., Dumond, J. B., Kashuba, A. D. M., Denti, P., & Gonzalez, D. (2023). Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(7), 638–649. https://doi.org/10.1002/phar.2703

  • van der Laan, L. E., Garcia-Prats, A. J., McIlleron, H., Abdelwahab, M. T., Winckler, J. L., Draper, H. R., Wiesner, L., Schaaf, H. S., Hesseling, A. C., & Denti, P. (2023). Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 67(12), e00611-23. https://doi.org/10.1128/aac.00611-23

  • van der Laan, L. E., Hesseling, A. C., Schaaf, H. S., Palmer, M., Draper, H. R., Wiesner, L., Denti, P., & Garcia-Prats, A. J. (2023). Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children. Journal of Antimicrobial Chemotherapy, 78(10), 2481–2488. https://doi.org/10.1093/jac/dkad257

  • Waalewijn, H., Szubert, A. J., Wasmann, R. E., Wiesner, L., Chabala, C., Bwakura-Dangarembizi, M., Makumbi, S., Nangiya, J., Mumbiro, V., Mulenga, V., Musiime, V., Monkiewicz, L. N., Griffiths, A. L., Bamford, A., Doerholt, K., Denti, P., Burger, D. M., Gibb, D. M., McIlleron, H. M., … Team, for the C. with H. in A. – P. and A. of S. second-line antiretroviral regimens (CHAPAS-4) T. (2023). First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Clinical Infectious Diseases. https://doi.org/10.1093/CID/CIAD267

  • Wasmann, R. E., Masini, T., Viney, K., Verkuijl, S., Brands, A., Hesseling, A. C., Mcilleron, H., Denti, P., & Dooley, K. E. (2023). A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis. Frontiers in Pharmacology, 14, 655. https://doi.org/10.3389/fphar.2023.1055329